Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald began coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a note issued to investors on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating on the stock.

A number of other equities research analysts have also weighed in on TARA. Guggenheim restated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $22.50.

Protara Therapeutics Trading Down 1.2 %

Shares of Protara Therapeutics stock opened at $4.02 on Friday. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48. The company has a market cap of $82.93 million, a PE ratio of -1.43 and a beta of 1.69. The company has a 50 day moving average of $4.45 and a 200-day moving average of $3.46.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.09. Research analysts forecast that Protara Therapeutics will post -3.32 earnings per share for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TARA. XTX Topco Ltd acquired a new position in shares of Protara Therapeutics in the 3rd quarter worth approximately $60,000. Geode Capital Management LLC lifted its holdings in Protara Therapeutics by 21.0% in the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock valued at $311,000 after buying an additional 29,514 shares during the period. Bailard Inc. bought a new stake in Protara Therapeutics during the fourth quarter valued at $157,000. Oppenheimer & Co. Inc. grew its holdings in Protara Therapeutics by 12.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock worth $1,064,000 after acquiring an additional 22,301 shares during the period. Finally, RA Capital Management L.P. raised its position in shares of Protara Therapeutics by 78.9% in the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after acquiring an additional 1,500,000 shares in the last quarter. 38.13% of the stock is owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.